Skip to Content

Open letter to Gilead: Global civil society calls for no patents or exclusivities on potential COVID-19 treatment

Hi All

Apologies for sending this mail again but the link shared seem to be broken. Sharing the link again here: 

More than 150 organizations and individuals from global health movement sent a letter today to Gilead’s CEO sharing concerns about Gilead’s current approach to remdesivir, which may obscure access to this potentially critical treatment for COVID-19.

Gilead holds primary patents of remdesivir in more than 70 countries that may block generic entry until 2031. In the letter, Gilead was urged to take immediate actions to:

- Declare that Gilead will not enforce and claim exclusive rights on patents and regulatory and trial data, or any other types of exclusivity anywhere in the world;

- Make publicly available all data, sample products, and know-how that are needed for generic development and for regulatory processes, to facilitate the production and supply by generic manufacturers worldwide; and

- Improve transparency by disclosing its manufacturing capacity and existing supply and allow independent and proper governance over the allocation of the treatment according to medical needs. 

Attached is the letter for your reference. Do contact us in case you have any queries.



Shailly Gupta
MSF Access Campaign 
+41- 79 203 13 02



About Médecins Sans Frontières (MSF) Access Campaign

In 1999, in the wake of Médecins Sans Frontières (MSF) being awarded the Nobel Peace Prize, MSF launched the Access Campaign. Its purpose has been to push for access to, and the development of life-saving and life prolonging medicines, diagnostic tests and vaccines for patients in MSF programmes and beyond.

Médecins Sans Frontières (MSF) Access Campaign
Rue de Lausanne 78
P.O Box 1016
CH-1211 Geneva 1